

**August 25, 2009**  
**Announcement no. 22**

### **Cash issue, private placement**

---

On this date, the board of directors for BioPorto A/S decided to carry out a cash issue, private placement.

The capital increase will take place by means of the board's exercise of the authorization stipulated in Article 15a of the Company's Articles of Association, whereby the board is authorized until 31 March 2014 to increase the capital stock on one or more occasions by issuing new shares up to the nominal value of DKK 100,000,000.

The capital increase is being carried out in the form of a cash issue for a limited number of shareholders without a pre-emptive right for the Company's previous shareholders. The offering is a minimum of 2,000,000 shares and a maximum of 3,830,000 new shares at the price of DKK 3 each, equivalent to the nominal value of DKK 6,000,000 to DKK 11,490,000. In the event the maximum number of shares offered are subscribed to, the new shares equate to almost 10% of BioPorto's registered capital stock before the capital increase, thus making the cash issue exempt from the obligation to provide a prospectus.

The same rights apply to newly subscribed shares as to the existing shares, whereby it is specifically remarked that the new shares are transferable and freely negotiable.

The subscription price is set at DKK 3.97 per share. This market price is the weighted average of the listed price for BioPorto A/S shares over the past ten (10) trading days at NASDAQ OMX Copenhagen prior to the board's decision made today.

The subscription period begins on 26 August 2009 and ends on 25 September 2009. The board uses its own discretion to determine whether the subscription of shares will be wholly or partly accepted by the Company. In this respect, the board may decide that one, more or all subscription commitments must be reduced or cease entirely, e.g. as a result of changes in the market situation. In the event of oversubscription, the board will make a decision regarding the allocation of the shares.

The Company will arrange for the inclusion of the new shares for trading on NASDAQ OMX Copenhagen.

#### *Proceeds and use of proceeds*

The purpose of the capital infusion is to safeguard the Company's resources, to lay the best foundation for completing and marketing the new homogenous NGAL assay and to secure the essential patent rights, thus supporting the Company's operations and sources of income. At the same time, the capital infusion will minimize the Company's financial risks and make the Company more flexible in the ongoing licensing negotiations.

The total proceeds from the share issue amount to DKK 15.2 million, of which transaction costs – budgeted at DKK 0.5 million – must be deducted. Based on the present level of activity, the capital infusion will secure the Company's operations into 2011.

#### **Further information:**

Thea Olesen, CEO  
Christina Tønnesen, Investor Relations  
Tel. +45 45 29 00 00, e-mail [investor@bioporto.com](mailto:investor@bioporto.com)